128 related articles for article (PubMed ID: 1966866)
1. Opioid activities of morphiceptin-like peptides latent in various natural proteins.
Shimohigashi Y; Sakaguchi K; Sakamoto H; Waki M; Costa T
Pept Res; 1990; 3(5):216-23. PubMed ID: 1966866
[TBL] [Abstract][Full Text] [Related]
2. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro amide bond in the bioactive conformation.
Keller M; Boissard C; Patiny L; Chung NN; Lemieux C; Mutter M; Schiller PW
J Med Chem; 2001 Nov; 44(23):3896-903. PubMed ID: 11689075
[TBL] [Abstract][Full Text] [Related]
3. Opioid receptor binding and in vivo antinociceptive activity of position 3-substituted morphiceptin analogs.
Fichna J; do-Rego JC; Costentin J; Chung NN; Schiller PW; Kosson P; Janecka A
Biochem Biophys Res Commun; 2004 Jul; 320(2):531-6. PubMed ID: 15219861
[TBL] [Abstract][Full Text] [Related]
4. Potent morphiceptin analogs: structure activity relationships and morphine-like activities.
Chang KJ; Wei ET; Killian A; Chang JK
J Pharmacol Exp Ther; 1983 Nov; 227(2):403-8. PubMed ID: 6313901
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs.
Janecka A; Fichna J; Kruszynski R; Sasaki Y; Ambo A; Costentin J; do-Rego JC
Biochem Pharmacol; 2005 Dec; 71(1-2):188-95. PubMed ID: 16288997
[TBL] [Abstract][Full Text] [Related]
6. Dermenkephalin (Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2): a potent and fully specific agonist for the delta opioid receptor.
Amiche M; Sagan S; Mor A; Delfour A; Nicolas P
Mol Pharmacol; 1989 Jun; 35(6):774-9. PubMed ID: 2543911
[TBL] [Abstract][Full Text] [Related]
7. Topochemical analysis of morphiceptin and dermorphin bioactivities.
Yamazaki T; Ro S; Goodman M
Biochem Biophys Res Commun; 1991 Dec; 181(2):664-70. PubMed ID: 1661586
[TBL] [Abstract][Full Text] [Related]
8. Morphiceptin and beta-casomorphin-5 analogues containing a reduced peptide bond: selective mu-receptor agonists and a novel mu antagonist, H-Tyr-Pro psi (CH2-NH)Phe-Pro-Gly-OH.
Delaet NG; Verheyden PM; Tourwe D; Van Binst G; Davis P; Burks TF
Biopolymers; 1992 Aug; 32(8):957-69. PubMed ID: 1330047
[TBL] [Abstract][Full Text] [Related]
9. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of cyclic opioid peptide analogues containing a phenylalanine residue in the 3-position.
Schiller PW; Nguyen TM; Maziak LA; Wilkes BC; Lemieux C
J Med Chem; 1987 Nov; 30(11):2094-9. PubMed ID: 2822930
[TBL] [Abstract][Full Text] [Related]
11. Conformational features responsible for the binding of cyclic analogues of enkephalin to opioid receptors. III. Probable binding conformations of mu-agonists with phenylalanine in position 3.
Shenderovich MD; Nikiforovich GV; Golbraikh AA
Int J Pept Protein Res; 1991 Apr; 37(4):241-51. PubMed ID: 1654306
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of receptor affinity and selectivity of the natural delta-opioid agonist, dermenkephalin.
Sagan S; Amiche M; Delfour A; Mor A; Camus A; Nicolas P
J Biol Chem; 1989 Oct; 264(29):17100-6. PubMed ID: 2551895
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the structural parameters involved in the delta-opioid selectivity of several families of opioid peptides.
Guis C; Bruetschy L; Meudal H; Roques BP; Gacel GA
Int J Pept Protein Res; 1993 Jun; 41(6):576-86. PubMed ID: 8394291
[TBL] [Abstract][Full Text] [Related]
14. Opioid binding profile of morphiceptin, Tyr-MIF-1 and dynorphin-related peptides in rat brain membranes.
Sartania N; Benyhe S; Magyar A; Rónai AZ; Medzihradszky K; Borsodi A
Neuropeptides; 1996 Jun; 30(3):225-30. PubMed ID: 8819146
[TBL] [Abstract][Full Text] [Related]
15. Biological and conformational studies of [Val4]morphiceptin and [D-Val4]morphiceptin analogs incorporating cis-2-aminocyclopentane carboxylic acid as a peptidomimetic for proline.
Yamazaki T; Pröbsti A; Schiller PW; Goodman M
Int J Pept Protein Res; 1991 May; 37(5):364-81. PubMed ID: 1917292
[TBL] [Abstract][Full Text] [Related]
16. A topochemical approach to explain morphiceptin bioactivity.
Yamazaki T; Ro S; Goodman M; Chung NN; Schiller PW
J Med Chem; 1993 Mar; 36(6):708-19. PubMed ID: 8384662
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity studies of morphiceptin analogs: receptor binding and molecular determinants of mu-affinity and selectivity.
Loew G; Keys C; Luke B; Polgar W; Toll L
Mol Pharmacol; 1986 Jun; 29(6):546-53. PubMed ID: 3012319
[TBL] [Abstract][Full Text] [Related]
18. The role of amino-terminal sequence of beta-endorphin and dynorphin in the determination of opiate receptor type selectivity.
Chang JK; Chang KJ
Life Sci; 1983; 33 Suppl 1():267-9. PubMed ID: 6141489
[TBL] [Abstract][Full Text] [Related]
19. Interactions between the antiopiate Tyr-MIF-1 and the mu opiate morphiceptin at their respective binding sites in brain.
Zadina JE; Kastin AJ
Peptides; 1985; 6(5):965-70. PubMed ID: 2867527
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of new opiate-like peptides using a radioreceptor method].
Shestak KI; Sergeeva MG; Zaĭtsev SV; Kharchenko EP; Varfolomeev SD; Kalikhevich VN; Ardemasova ZA
Ukr Biokhim Zh (1978); 1990; 62(2):23-9. PubMed ID: 1973313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
